Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma is a research paper published in Neuro-Oncology (2025). On theSindex it has a DataRank of 0.273. It has been cited 5 times, with 5 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
4.57 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
NCI NIH HHS
Grant: UG1 CA232760
NCI NIH HHS
Grant: U10 CA180821
NCI NIH HHS
Grant: UG1 CA189825
NCI NIH HHS
Grant: U10 CA180882
NIH HHS
National Institutes of Health
NIH HHS
FWCI
3.54
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals